156 related articles for article (PubMed ID: 25322440)
1. Group Sequential Design for Randomized Phase III Trials under the Weibull Model.
Wu J; Xiong X
J Biopharm Stat; 2015; 25(6):1190-205. PubMed ID: 25322440
[TBL] [Abstract][Full Text] [Related]
2. Power and sample size for randomized phase III survival trials under the Weibull model.
Wu J
J Biopharm Stat; 2015; 25(1):16-28. PubMed ID: 24895942
[TBL] [Abstract][Full Text] [Related]
3. A practical simulation method to calculate sample size of group sequential trials for time-to-event data under exponential and Weibull distribution.
Jiang Z; Wang L; Li C; Xia J; Jia H
PLoS One; 2012; 7(9):e44013. PubMed ID: 22957040
[TBL] [Abstract][Full Text] [Related]
4. Adaptive sequential testing for multiple comparisons.
Gao P; Liu L; Mehta C
J Biopharm Stat; 2014; 24(5):1035-58. PubMed ID: 24926848
[TBL] [Abstract][Full Text] [Related]
5. Statistical aspects of the TNK-S2B trial of tenecteplase versus alteplase in acute ischemic stroke: an efficient, dose-adaptive, seamless phase II/III design.
Levin B; Thompson JL; Chakraborty B; Levy G; MacArthur R; Haley EC
Clin Trials; 2011 Aug; 8(4):398-407. PubMed ID: 21737464
[TBL] [Abstract][Full Text] [Related]
6. Estimation of hurst exponent for sequential monitoring of clinical trials with covariate adaptive randomization.
Yang Y; Zhu H; Lai D
Contemp Clin Trials; 2022 Sep; 120():106887. PubMed ID: 35988662
[TBL] [Abstract][Full Text] [Related]
7. Not too big, not too small: a goldilocks approach to sample size selection.
Broglio KR; Connor JT; Berry SM
J Biopharm Stat; 2014; 24(3):685-705. PubMed ID: 24697532
[TBL] [Abstract][Full Text] [Related]
8. A strategic view of randomized trial design in low-incidence paediatric cancer.
Sposto R; Stram DO
Stat Med; 1999 May; 18(10):1183-97. PubMed ID: 10363339
[TBL] [Abstract][Full Text] [Related]
9. Adaptive increase in sample size when interim results are promising: a practical guide with examples.
Mehta CR; Pocock SJ
Stat Med; 2011 Dec; 30(28):3267-84. PubMed ID: 22105690
[TBL] [Abstract][Full Text] [Related]
10. Group-sequential methods for adaptive seamless phase II/III clinical trials.
Stallard N
J Biopharm Stat; 2011 Jul; 21(4):787-801. PubMed ID: 21516569
[TBL] [Abstract][Full Text] [Related]
11. Three-component cure rate model for nonproportional hazards alternative in the design of randomized clinical trials.
Kim HT; Gray R
Clin Trials; 2012 Apr; 9(2):155-63. PubMed ID: 22353928
[TBL] [Abstract][Full Text] [Related]
12. Single-Arm Phase II Group Sequential Trial Design with Survival Endpoint at a Fixed Time Point.
Wu J; Xiong X
Stat Biopharm Res; 2014; 6(4):289-301. PubMed ID: 28890756
[TBL] [Abstract][Full Text] [Related]
13. Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology.
Horiguchi M; Hassett MJ; Uno H
Clin Trials; 2020 Dec; 17(6):597-606. PubMed ID: 32933339
[TBL] [Abstract][Full Text] [Related]
14. Statistical inference problems in sequential parallel comparison design.
Cui Y; Ogbagaber S; Hung HMJ
J Biopharm Stat; 2019; 29(6):1116-1129. PubMed ID: 31035859
[TBL] [Abstract][Full Text] [Related]
15. A note on sequential monitoring of select-the-winner design.
Lan KK; Chen F; Zhong B; Shun Z
J Biopharm Stat; 2015; 25(3):408-16. PubMed ID: 25645054
[TBL] [Abstract][Full Text] [Related]
16. Confidence intervals for odds ratio from multistage randomized phase II trials.
Cao S; Jung SH
Stat Med; 2024 May; 43(12):2359-2367. PubMed ID: 38565328
[TBL] [Abstract][Full Text] [Related]
17. Group sequential multi-arm multi-stage survival trial design with treatment selection.
Wu J; Li Y
J Biopharm Stat; 2024 Jul; 34(4):453-468. PubMed ID: 37455424
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized Clinical Trials.
Claggett B; Pocock S; Wei LJ; Pfeffer MA; McMurray JJV; Solomon SD
Circulation; 2018 Aug; 138(6):570-577. PubMed ID: 29588314
[TBL] [Abstract][Full Text] [Related]
19. Elicitation of prior distributions for a phase III randomized controlled trial of adjuvant therapy with surgery for hepatocellular carcinoma.
Tan SB; Chung YF; Tai BC; Cheung YB; Machin D
Control Clin Trials; 2003 Apr; 24(2):110-21. PubMed ID: 12689733
[TBL] [Abstract][Full Text] [Related]
20. A novel test to compare two treatments based on endpoints involving both nonfatal and fatal events.
Potthoff RF; Halabi S
Pharm Stat; 2015; 14(4):273-83. PubMed ID: 25894200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
